Veracyte
South San Francisco, United States· Est. 2008
Our genomic cancer tests provide physicians with molecular insights to help give their patients informed answers now and make personalized treatment plans for the future. Our high-performing tests support patient care across thyroid, prostate, bladder, breast, and lung cancers.
Private Company
Total funding raised: $215M
About
Our genomic cancer tests provide physicians with molecular insights to help give their patients informed answers now and make personalized treatment plans for the future. Our high-performing tests support patient care across thyroid, prostate, bladder, breast, and lung cancers.
Diagnostics
Funding History
4Total raised:$215M
PIPE$100MFeb 15, 2021
IPO$60MOct 3, 2013
Series B$35MNov 15, 2011
Series A$20MJun 15, 2010